Back to News
Market Impact: 0.2
Prelude Therapeutics, Lilly Partner To Evaluate PRT13722 In Breast Cancer Trial
Source: Nasdaq
Healthcare & Biotech
Prelude Therapeutics entered a clinical trial collaboration and supply agreement with Eli Lilly to evaluate PRT13722 in combination with Verzenio (abemaciclib) and Inluriyo (imlunestrant) in patients with HR+/HER2- breast cancer. The excerpt provides no trial timing, results, or financial terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
LLY0.20
PRLD0.60
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- Walmart to cover some GLP-1s, inhalers and insulin for employees at no cost as it expands benefits
- Evercore ISI cuts Foghorn Therapeutics stock rating on trial failure
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales